MIRMMirum Pharmaceuticals, Inc.
Is the business good?
Margins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is MIRM?
Mirum Pharmaceuticals, Inc. spent more than it took in: an operating loss of $834M on $618M of revenue, 12 months to Q2 2026.
Operating loss · on $618M of revenue · 12 months to Q2 2026
- Share count, year on year
- +27%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 46%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2021 | −906% |
| FY2022 | −170% |
| FY2023 | −59% |
| FY2024 | −26% |
| FY2025 | −4.3% |
Details›
- Operating margin12 months to Q2 2026
- −135%
- Net margin12 months to Q2 2026
- −139%
- Free cash flow margin
- −37%
- R&D as % of revenue
- 46%
- Revenue, trailing twelve months
- $618M
- Free cash flow, trailing twelve months
- −$229M
- Net income, trailing twelve months
- −$860M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.